El trading conlleva riesgos
Los CFDs son instrumentos complejos y tienen un alto riesgo de perder dinero rápidamente debido al apalancamiento.
El trading conlleva riesgos
Los CFDs son instrumentos complejos y tienen un alto riesgo de perder dinero rápidamente debido al apalancamiento.
Español (Latinoamérica)
Sangamo Therapeutics Inc
Cerrado
SectorSalud
0.37 -5.13
Resumen
Variación precio
24h
Mínimo
0.37
Máximo
0.39
Ingresos | -15M -35M |
|---|---|
Ventas | -18M 581K |
Margen de beneficio | -6,012.048 |
Empleados | 183 |
EBITDA | -15M -33M |
Recomendaciones | Comprar |
|---|---|
Estimación a 12 meses | +1438.46% upside |
Próximas Ganancias | 16 mar 2026 |
|---|
Capitalización de Mercado | -15M 160M |
|---|---|
Apertura anterior | 5.5 |
Cierre anterior | 0.37 |
Noticias sobre sentimiento de mercado
By Acuity
50%
50%
162 / 351 Clasificación en Healthcare
Puntuación técnica
By Trading Central
Confianza
Strong Bearish Evidence
Sangamo Therapeutics Inc Gráfico
El rendimiento pasado no es un indicador fiable de resultados futuros.
Noticias Relacionadas
Comparación entre iguales
Cambio de precio
Sangamo Therapeutics Inc Esperado
Precio Objetivo
By TipRanks
1438.46% repunte
Estimación a 12 meses
Media 6 USD 1438.46%
Máximo 10 USD
Mínimo 2 USD
De acuerdo con 2 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Sangamo Therapeutics Inc Dist en los últimos 3 meses.
Sentimiento
By Acuity
162 / 351 Clasificación en Salud
Noticias sobre sentimiento de mercado
Neutral
Volatilidad
Por debajo de la media
Volumen de Noticias (RCV)
Por debajo de la media
Finanzas
Gastos de venta y administración
Gastos operativos
Beneficio antes de impuestos
Ventas
Coste de ventas
Beneficio bruto de ventas
Gasto por intereses de deuda
EBITDA
Beneficio operativo
$
Acerca de Sangamo Therapeutics Inc
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.
Live chat